MedWatch

Is biotech headed for a fall in the US?

A US media outlet fears that the recent wave of biotech IPOs could create a bubble. Danish major investor, Florian Schönharing, NB Capital, has a more nuanced view of the development in the country – but one thing remains “inexplicable”.

Foto: PR

Is the biotech IPO frenzy in the US headed for a fall?

That is the question posed by the editor of a renowned US biotech news website, John D. Carroll, in a special report following the latest wave of IPOs in the US where several immature companies have entered the market at excessive prices.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier